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Abxtract Cisplatin damages cochlear hair cells and spiral ganglion neurons through cell death signaling pathways
that are not fully understood. We used focused apoptosis gene microarrays to study early changes in gene expression
in cochlear cultures from P3 neonatal rats treated with cisplatin（0.2 mM）. After 12 hours of cisplatin treatment, more
than 50% of the 96 genes on the array showed a significant decrease in expression, consistent with widespread cell
death. However, after 3 hours of cisplatin treatment, 10 genes showed significant increase in expression in total co⁃
chlear tissue. In experiments with subsets of cochlear tissues, at 3h, cisplatin induced increased expression of 12
genes in the cochlear sensory epithelium（basilar membrane）and 11 genes in the spiral ganglion（tissue of Rosenthal
’s canal, containing the spiral ganglion）. These included pro- and anti-apoptotic genes involved in the p53 signaling
pathway, TNF receptor family, NF-kappaB pathway, death domain family, death effector domain family, Bcl-2 fami⁃
ly, CARD family, TRAF family, and GTP signal transduction. Although the changes in gene expression showed an
overlap between basilar membrane and spiral ganglion, other changes, which may reflect the unique response of each
tissue, were also observed. Pifithrin-α blocked cisplatin-induced up-regulation of genes in the p53 signaling path⁃
way when assayed by both superarray and real time PCR. The data add to our understanding of the involvement of
p53 in cisplatin-induced ototoxicity and otoprotection, conferred by the p53 inhibitor Pifithrin-α.
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Introduction
Cisplatin is widely used as an anti-tumor agent. Its
use, however, is limited by serious side effects, includ⁃
ing nephrotoxicity, neurotoxicity and ototoxicity［1 － 6］.
DNA is considered the primary target of cisplatin, and
DNA damage results from the formation of adducts,
which consist mainly of intra-strand cross-links. These,
in turn, lead to an arrest of the cell cycle by blocking
DNA synthesis, inhibition of RNA transcription, and in⁃
duction of pro-apoptotic and pro-survival genes［7］. The
ototoxic effects of cisplatin begin with high frequency
hearing loss［8－13］. The process begins in the cochlear tis⁃
sue, where cisplatin increases the production of free rad⁃
icals［14－ 16］ and causes a decline in antioxidant enzymes
［16－19］. The activity of free radicals also leads to apoptosis
by activating caspases［8, 16, 20, 21, 22］. The mechanism for the
initiation of cisplatin-induced apoptosis in the early
changes of gene expression is not yet fully understood.
However, activation of some apoptotic signaling path⁃
ways has been reported.
Specifically, research has shown that cell surface
death receptors, Fas and Tumor Necrosis Factor Recep⁃
tor（TNFR）, are activated by cisplatin in cochlear tis⁃
sue. These receptors signal the activation of an initiator
caspase, caspase-8, and downstream executi－ oner
caspases, such as caspase-3, caspase-7 and cas⁃
pase-6［23－25］. Cisplatin has also been reported to initiate
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apoptosis in cochlear derived cells by a second pathway
that involves the release of cytochrome c from mitochon⁃
dria and subsequent activation of Apaf-1 and pro-cas⁃
pase-9, followed by effector caspase-3［26］. The mito⁃
chondrial pathway, however, does not appear to play a
role in apoptosis of cochlear hair cells in in vivo studies
with co-administration of cisplatin and ethacrynic acid
in chinchilla［27］.
A third pathway might also be involved in the induc⁃
tion of apoptosis in cochlear cells. This mechanism in⁃
volves members of the mitogen-activated protein kinase
（MAPK）family, including extracellular signal-regulat⁃
ed kinases 1 and 2（ERK1/2）, which activate p53 as a
transcription factor in response to DNA damage, result⁃
ing in the subsequent activation of caspases［28 － 32］.
This MAPK pathway can be effectively blocked by treat⁃
ment with PD98059［30, 33－38］.
A fourth pathway was found in squamous cells that
up-regulate p53, its downstream targets, Bax, and then
caspase-3［39］. In proliferating HEI-OC1 cells derived
from the organ of Corti［40］, cisplatin caused an increase
in p53 at 3h prior to activating Bax, caspase-8, and cas⁃
pase-9［26］. Bax downstream of p53 can be induced by
up-regulation of p53, which then activates caspase-3
through either caspase-8 or casepase-9. In our previous
study, we also found that p53 plays an important role in
initiating cisplatin-induced apoptosis in cochlear and
vestibular hair cells and that the activation of p53 can
be blocked by Pifithrin-α（PFT）, a powerful p53 inhibi⁃
tor［41］.
In the current study, to better understand apoptotic
mechanisms of cisplatin ototoxicity and the protective ef⁃
fects of PFT, we investigated changes in apoptotic gene
expression using focused apoptosis gene microarrays
with cochlear organotypic cultures treated with either
cisplatin or cisplatin plus PFT. We identified several
genes related to p53 that appeared to be up-regulated in
early responses to cisplatin and confirmed these observa⁃
tions using a semi-quantitative real-time PCR assay.
Experimental Procedures
Animals
The aim of the current experiment was to determine
early changes in apoptotic gene expression induced by
cisplatin in the cochlea. Three-day-old(P3) Fisch⁃
er-344(F344) rats were used for this study. Pregnant
rats were obtained from the Charles River Laboratories
（Wilmington, MA）. At P3, the postnatal rats were de⁃
capitated. To examine gene expression in the basilar
membrane and spiral ganglion, the stria vascularis and
spiral ligament were removed. To detect apoptotic gene
expression specific to either the basilar membrane or
spiral ganglion, the total Rosenthal’s canal, containing
spiral ganglion neurons, was separated from the basilar
membrane by microdissection along the inner edge of
the basilar membrane.
Organotypic cultures
Primary cultures of cochlear tissue were maintained
in a manner similar to that described in previous studies
［42］. For experiments with total cochlear tissues, cochleae
containing both spiral ganglion neurons and basilar
membrane were incubated in 5% CO2 at 37℃ , for 3 or
12 hours without cisplatin, with 0.2 mM cisplatin（Sig⁃
ma Chemical Co., St. Louis, MO）, or with 0.2 mM cispla⁃
tin plus 100μM PFT（Calbiochem, Carlsbad, CA）in a
serum-free medium in 35 mm polystyrene dishes（Fal⁃
con, Becton Dickinson, Franklin Lakes, NJ）. Fourteen
cochleae were incubated under each experimental condi⁃
tion. The serum-free medium consisted of bovine serum
albumin［Sigma A-4919］2g, Serum-Free Supplement［Sigma I-1884］2
ml, 20% Glucose［Sigma G-2020］ 4.8 ml, Penicillin G［Sigma P-3414］
0.4 ml, 200 mM Glutamine［Sigma G-6392］2 ml, and 1
× BME［Sigma B-1522］190.8ml）. To examine the spi⁃
ral ganglion, total Rosenthal’s canal from 20 cochleae
was cultured with or without 0.2 mM cisplatin in se⁃
rum-free medium for 3 hours. For the experiments with
the serum free medium alone, the cochlear basilar mem⁃
brane, consisting of hair cells and supporting cells from
20 cochleae, were collected and cultured with or without
0.2 mM cisplatin for 3 h.
Cisplatin and PFT treatment
To examine early changes in gene expression, cul⁃
tures were treated with or without 0.2 mM cisplatin or
100 μM PFT. Incubations were then terminated at 3
hours. Experimental conditions were repeated at least
eight times. For detection of gene changes in the period
of cell degeneration（late changes）, one group of total co⁃
chlear tissue was cultured with cisplatin and terminated
at 12 hours.
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PCR gene array
The Oligo GEArray (GEA) Apoptosis Series Kit（Su⁃
perarray Inc., Frederick, MD）was used according to the
manufacturer’s instructions. An Oligo GEA designed to
profile the expression of 96 key rat genes involved in
apoptosis was used for total cochlear tissue examination.
An Oligo GEArray for the expression of 128 key apoptot⁃
ic rat genes, including all of the above-mentioned 96
genes, were used in a separate examination of the basi⁃
lar membrane and spiral ganglion. In both arrays, the
genes were grouped into 11 categories, according to
their functional and structural features, and included the
TNF ligands, TNF receptors, bcl-2 related genes, cas⁃
pases, IAP, TRAF, CARD, death domain family mem⁃
bers, death effector domain family members, and CIDE
domain family members, as well as genes involved in the
p53 and ATM pathways.
In brief, total RNA was prepared using the RNeasy
Mini Kit（74104, Qiagen Inc., Valencia, CA）. Synthesis
of cDNA and amplification of cRNA were performed us⁃
ing a Truelabeling-AMP linear RNA amplification kit
（SuperArray Inc., catalog number 1005）. 1.5-3.5ug to⁃
tal RNA were mixed with GEA primers in RNase-Free
H2O, to a final volume of 10 μl, and incubated at 70℃
for 10 min. Afterwards, a 10 μl Synthesis Master Mix
（containing 4 μl RNase-free H2O, 4 μl 5X cDNA syn⁃
thesis buffer, 1 μl RNase inhibitor, and 1 μl cDNA syn⁃
thesis enzyme mix）was added to initiate reverse tran⁃
scription. The tube was incubated at 42℃ for 50 min
and then at 37℃ for 5 min. A 20 μl Amplification Mas⁃
ter Mix（containing 2μl 10 mM of Biotinylated-UTP, 16
μl of 2.5X RNA Polymerase Buffer, and 2 μl of RNA
Polymerase Enzyme）was added to the tube which was
then incubated overnight at 37℃.
cRNA was purified using a SuperArray ArrayGrade
cRNA Cleanup Kit（GA-012）. Hybridization was per⁃
formed by adding 0.75ml of the hybridization buffer sup⁃
plied by the manufacturer. Arrays were incubated over⁃
night at 60℃ in hybridization cylinders with Superarray
Hybridization Solution containing 5-20 μg biotin-la⁃
beled cRNA. Arrays were washed and imaged with che⁃
miluminescence, using alkaline phosphatase-conjugat⁃
ed streptavidin and CDP-Star chemiluminescent sub⁃
strate（Chemiluminescent Detection Kit (D-01, Superar⁃
ray Inc.）. The exposure was examined and images ana⁃
lyzed using a Kodak Image 2000 and Kodak 1D software
（Rochester, NY）. Data were normalized to back⁃
ground-corrected levels from the housekeeping gene,
glyceraldehydes 3-phosphate dehydrogenase （GAP⁃
DH）. The experiments were repeated 8 times for the to⁃
tal cochlear tissue, including the basilar membrane and
spiral ganglion neurons, 8 times for the spiral ganglion,
and 12 times for the basilar membrane. Genes in total
cochlear tissue and for spiral ganglion specimens were
subjected to further analysis if they demonstrated either
increase or decrease in 6 of the 8 experiments, or a con⁃
sistent response in 8 of the 12 experiments for basilar
membrane and spiral ganglion specimens.
Semi-quantitative Real-Time PCR
Total RNA was isolated from cochlea cultures using
the RNeasy Mini Kit（Qiagen）and RNase-free DNase
set（Qiagen）. The total RNA recovered was dissolved in
water, and the total RNA concentration was determined
by measuring adsorption at 260 nm on a spectrophotome⁃
ter（Beckman Coulter, DU 640）. RNA integrity was veri⁃
fied by electrophoresis on 1% agarose gels.
First-strand complementary DNA was synthesized by
priming with oligo-dT15（Ambion, Foster City, CA）.
This primer has the advantage of cDNA synthesis start⁃
ing at the boundary poly-A-tail adjacent to mRNA. Re⁃
verse transcription was performed in 20 μl reactions. Ini⁃
tially, 2 μg RNA and 2 μl（2.5 μm）oligo-dT primer
were mixed to a 12 μl volume, heated to 83℃ for 3 min
and placed on ice; then 2 μl 5X buffer, 1 μl（10 units）
RNase inhibitor, 4 μl（2 mM stock） dNTP, and 1 μl
（100 units）reverse transcriptase were added（all compo⁃
nents manufactured by Ambion）. The solution was incu⁃
bated at 42℃ for 60 min and the reaction terminated by
heating at 95℃ for 10 min.
Polymerase chain reaction: Quantitative RT-PCR was
performed on an Opticon II（MJ Research） instrument
using a DyNAmo SYBR Green I PCR Kit（Finnzymes,
F-400S, Miami, FL）. The PCR reaction mixture consist⁃
ed of 10 μl of Master SYBR Green I mix, 5μl of forward
and reverse primers（1.2 mM stocks）, and cDNA（5 μl,
100 ng）. The primers for GAPDH, MCl-1, GADD45a,
and BNIP3 were provided by Superarray Inc.
（PPR06557A-24, PPR0641A-24, PPR06489A-24,
and PPR06513A-24）. Cycling started with denaturation
at 95℃ for 10 min, followed by 45 cycles of denaturation
R
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at 94℃ for 30 sec, annealing at 55℃ for 30 sec, and ex⁃
tension at 72℃ for 60 sec. The fluorescence signals
were acquired from 72-88℃ each for 1 sec after each cy⁃
cle. The GAPDH mRNA level, determined under identi⁃
cal conditions in each RNA sample, was used as an in⁃
ternal control to normalize the RNA levels from different
samples.
Data analysis: A standard curve was generated by plot⁃
ting the threshold cycle（Ct）value versus the log of in⁃
put RNA equivalent（0.1-100 ng calculated from the di⁃
lution factor of the RT products）. The fold changes be⁃
tween control and test cultures, normalized to GAPDH,
were determined using the following equation: Fold
change=2-△（△Ct）, where △Ct = Ct（target）- Ct（gapdh）and△（△
Ct）=△Ct（treated）-△Ct（untreated）（Livak et al., 2001). PCR
products were visualized on 1% agarose gels to ensure a
single product of the correct length.
Statistical analysis: All data are presented as mean ±
1 standard error of the mean. Differences were analyzed
using one-way ANOVA（Sigma Stat. 2.03）with p< 0.05
considered statistically significant.
Results
Changes in apoptotic genes expression in total co⁃
chlear tissue
In our initial experiments, we treated total cochlear tis⁃
sue cultures with 0.2 mM cisplatin and assayed for the
expression of cisplatin-induced genes using a rat micro⁃
array designed for the detection of 96 key apoptotic
genes. Over 50% of the genes assayed underwent a de⁃
crease in expression at 12 hours post-cisplatin treat⁃
ment. This response was observed at this time point 3
out of 3 times, at which cisplatin induced an increase in
only two of the genes assayed-Tnfaip2 and Tnfrsfl2a,
both in the tumor necrosis factor（TNF）receptor super
family（Figure 1B）. This result is consistent with the
fact that many cells were in the process of dying at this
time point［27］. Remarkably, 10 genes were up-regulated
only 3 hours post-cisplatin at least 6 times in each of 8
repeated measurements. The expression levels of the re⁃
maining 86 genes showed no change at 3h（Figure 1A）.
Six of the 10 early genes（Gadd45a, Myd88, Rrad, Tn⁃
faip2 protein, Tnfrsfl2a, and Tnfrsf1a）were pro-apoptot⁃
ic and involved in p53-mediated signaling, the TNF re⁃
ceptor family, Death Domain family, BCL-2 family,
CARD family, and GTP signaling. Four of the 10 early
genes, Bcl10, Birc3, Bnip3, and Mcl1, are members of
the anti-apoptotic family, involved with the NF-kappaB
pathway, CARD family, IAP family, Bcl-2 family, and
P53 signaling pathway（Figure 2）.
Consistent with our previous discovery of the otopro⁃
tective properties of PFT ［41］, in the total cochlear tissue
assays, the p53 inhibitor, PFT, blocked the cisplatin-in⁃
duced increase in the expression of each of the ten early
Fig.1 Apoptosis gene arrays at 3 hours post-cisplatin treatment, showing increased expression（black circle）of 10 genes
and no change in the rest（86 genes）. In contrast, in cultures with 12 hours of cisplatin, great reduction in expression is seen
for most genes（gray circle）, except 2 genes with increased expression（black circle）.
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genes（Figure 3）.
Changes in apoptotic genes expression in spiral gan⁃
glion neurons
In the spiral ganglion neuron fraction, 11 genes
showed a large increase 3 hours after cisplatin treat⁃
ment. These genes were Bcl10, Bcl2a1, Birc2, Fadd,
Gadd45, Mcl1, Myd88, Rrad, Tnfrsf11b, Tnfrsf1a, and
Tnfrsf1b. The apoptotic signaling pathways included the
p53/DNA damage family, TNF Receptor family, Bcl-2
family, IAP family, NF-kappaB pathway, CARD family,
Death Domain family, and GTP signaling family. Four of
the 11 early-responding genes in the spiral ganglion,
Bcl10, Bcl2a1, Mcl1, and Birc2, are anti-apoptotic（Fig⁃
ure 4）. The remaining 7 genes are pro-apoptotic（Fadd,
Gadd45, Myd88, Rrad, Tnfrsf11b, Tnfrsf1a, and Tn⁃
frsf1b）.
Changes in apoptotic genes expression in cochlear
epithelium
In the basilar membrane fraction containing the hair
cells and supporting cells, 12 genes showed a large in⁃
crease in expression 3 hours after cisplatin treatment.
These included Bcl2a1, Birc3, Bok, Casp3, Cflar,
Cradd, Gadd45, Mcl1, Myd88, Tnfrs12a, Tnfrsf1a, and
Traip. The functional characteristics of these genes are
involved in the p53／DNA damage family, TNF recep⁃
tor family, NF-kappaB pathway, Bcl-2 family, CARD
family, death effector domain family, death domain fami⁃
ly, and TRAF family. Four of these genes are classified
as anti-apoptotic genes（Bcl2a1, Mcl1, Birc3, and Cf⁃
Fig.2 Ten genes in total cochlear tissue cultured with cisplat⁃
in for 3 hours showing significant increased expression-more
than 2 times of the untreated control cochlear tissue.
Fig.3 Effect of PFT. The same 10 genes in the total cochlear tissue
with increased expression in Fig. 2 now showing greatly reduced ex⁃
pression after 3 hours of treatment with cisplatin and PFT.
Fig.4 Expression of 11 apoptotic genes in spiral ganglion neu⁃
ron specimens showing a significant increase 3 hours after cispla⁃
tin treatment. These genes include 7 apoptotic and 4 anti-apop⁃
totic genes. The major apoptotic pathways are listed above the
genes in bold.
Fig.5 Eight apoptotic genes and 4 anti-apoptotic genes
showing increased expression in cochlear basilar epithelium
specimens 3 hours after cisplatin treatment.
·· 65
Journal of Otology 2009 Vol. 4 No. 2
lar）, while the remaining 8 genes are pro-apoptotic
（Bok, Casp3, Cradd, Gadd45, Myd88, Tnfrs12a, Tn⁃
frsf1a, and Traip）（Figure 5）.
Protective effects of PFT with RT-PCR detection
Data from semi-quantitative real-time PCR showed
that mRNA levels in 3 genes, Bnip3, Gadd45a, and
Mcl1, were significantly increased in cisplatin-treated
total cochlear tissue. However, these cisplatin-induced
elevations were greatly reduced by treatment with the
p53 inhibitor PFT（Figure 6）. Importantly, the three
genes are involved directly or indirectly in the p53 sig⁃
naling pathway.
Discussion
Cisplatin is widely used in therapy for many cancers.
Cisplatin affects its anti-neoplastic activity by binding
with DNA and forming inter- and intra-strand
cross-links and protein-DNA cross-links that inhibit
DNA replication and RNA transcription. This, in turn,
leads to cell cycle arrest and signals the initiation of
apoptosis［43－47］. Despite its abilities to arrest the division
of cancer cells and to reduce tumor size by programmed
cell death, clinical doses of cisplatin are limited by se⁃
vere toxic side effects in the inner ear and the kidney.
Each of these organs contains cells that are particularly
susceptible to cisplatin’s ability to induce apoptosis.
Nephrotoxicity can be managed to a degree by adequate
hydration before and during treatment ［48］. Ototoxicity
can be reduced with antioxidants［49］ and other agents［50,
51］, although these approaches do not yet afford complete
protection of hearing and have only just begun to be test⁃
ed in clinical trials［49］. A great deal of effort has been
made to synthesize and test cisplatin derivatives. The
second generation platinum based drug, carboplatin,
and the third generation drug, oxaloplatin, have greatly
reduced ototoxic side effects［52, 53］. However, these deriva⁃
tives are not effective against all cancers that can be suc⁃
cessfully treated by cisplatin, e.g., colorectal cancers［54］.
Thus, there is still a pressing need to develop strategies
for protection from cisplatin ototoxicity.
In our previous studies of cisplatin-induced caspase
activities, we found that caspase-8 was the first to be ac⁃
tivated in cisplatin-treated cochlear hair cells［27］. Be⁃
cause caspase-8 is activated in response to receptors
with a death domain on the cell membrane, it is not sur⁃
prising that, in the present study, we found that tran⁃
scription of several apoptotic genes of the tumor necrosis
factor receptor super family was up-regulated soon after
cisplatin administration.
When cisplatin enters the cell, it undergoes a series
of non-enzymatic hydration reactions leading to the for⁃
mation of DNA adducts. DNA damaged by cisplatin ad⁃
ducts can signal repair mechanisms and other pro-sur⁃
vival responses. In addition, aberrant DNA-protein in⁃
teractions, at the sites of cisplatin adducts, can signal
the initiation of programmed cell death pathways. The
fate of the cell then balances between the survival and
the apoptotic response. For example, an Mcl-1 gene
may interact with Bax, which promotes cell death as a
homodimer, but this also can heterodimerize with Bcl-2
to promote cell viability［55］.
P53 is an important executioner of the apoptotic re⁃
sponse. This tumor suppressor gene is activated in re⁃
sponse to DNA damage, stress, radiation damage, and
many chemotherapeutic agents, including cisplatin. Con⁃
sistent with DNA as a primary biological target of cispla⁃
tin, p53 has been implicated in initiating the process of
apoptosis in cochlear hair cells［41］. In the current experi⁃
ments, we found that the expression of several apoptotic
or anti-apoptotic genes directly or indirectly related to
p53 signaling pathways were up-regulated in all three
cochlear tissue types tested. The results are consistent
with previous findings of cisplatin-induced p53 activa⁃
tion in cochlear and vestibular hair cells［41］.
During the early stages of cisplatin-induced damage
to the organ of Corti and spiral ganglion, both apoptotic
and anti-apoptotic genes were up-regulated in response
Fig.6 Semi-quantitative real-time PCR showing reduced ex⁃
pression of 3 apoptotic genes involved in p53 signaling path⁃
way at the mRNA level.
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to stress and DNA damage. In total cochlear tissue, cis⁃
platin significantly increased the expression of 10 genes
related to 8 major cell death pathways (the p53 signaling
pathway, TNF receptor family, NF-kappaB pathway,
CARD family, death domain family, BCL-2 family, IAP
family, and GTP signal transduction). In specimens con⁃
taining spiral ganglion neurons, cisplatin induced in⁃
creased expression of 11 genes, belonging to the same 8
main cell death pathways. In cochlear sensory epitheli⁃
um, 12 genes were up-regulated by cisplatin. These in⁃
cluded genes in 7 of the 8 apoptotic pathways affected in
the total cochlear tissue and in spiral ganglion contain⁃
ing tissue with no change in expression of GTP signaling
genes. In addition, cisplatin induced expression of mem⁃
bers of the TRAF family. When comparing changes in
the cochlear sensory epithelium to the spiral ganglion
and to total cochlear tissue, we found that early respond⁃
ing genes in cochlear epithelium are also involved in the
TRAF family, but had no change in gene expression rele⁃
vant to GTP signaling transduction. Despite the overlap
gene expression between cochlear sensory epithelium
and spiral ganglion neurons, some differences were ob⁃
served, which may reflect the unique response of each
tissue. It is intriguing to consider the differences in
up-regulated apoptotic genes among the three samples
assayed, total cochlear tissue, cochlear sensory epitheli⁃
um and spiral ganglion neurons. We speculate that
cell-specific differences in gene expression may have
been concealed by examining mixed tissues, each with
different levels of gene expression. However, several
genes were consistently shown to be up-regulated 3
hours after cisplatin treatment. The results suggest that
apoptotic and anti-apoptotic genes in the cochlear epi⁃
thelium and spiral ganglion neurons are rapidly activat⁃
ed in response to cisplatin-induced damage to DNA and
to the cell membrane.
The findings show that numerous genes and multiple
apoptotic pathways were involved in cisplatin-induced
cell apoptosis. The apoptotic pathways by cisplatin treat⁃
ment involve the p53/DNA damage family, TNF recep⁃
tor family, NF-kappaB pathway, Bcl-2 family, CARD
family, death effector domain family, death domain fami⁃
ly, and TRAF family. When analyzing the relationship
between the 20 changed genes and their apoptotic path⁃
ways, we find that many of these genes are involved in
multiple apoptotic pathways, and most of them directly
or indirectly are involved in the important tumor necro⁃
sis factor receptor super family and the p53/DNA dam⁃
age signaling pathway.
The tumor necrosis factor receptors can trigger the sig⁃
naling pathway, converging on the activation of NF-kap⁃
paB, which forms the basis for many physiological and
pathological processes［56］. Therefore, the early changed
six genes（Bcl10, Birc2, Cflar, Fadd, Myd88, and Tn⁃
frsf1a） in the NF-kappaB pathway are also tightly
linked with cell death factor receptors on the cell mem⁃
brane that belong to TNF receptor super family.
Many genes in the Bcl-2 family are also crucial mem⁃
bers of the p53 signaling pathway. The Bcl-2 protein is
a strong prognostic indicator related to p53 activity［57］.
Thus, the p53 pathway and its complex are thought to in⁃
teract with the Bcl-2 family［36, 58］. As such, the 4 genes
（Bcl2a1, Bnip3, Mcl1, and Bok）in the Bcl-2 family al⁃
so relate to the p53 pathway. In addition, a member of
the CARD（caspase recruitment domain）family（Birc3）,
and the member of IAP（inhibitor of apoptosis protein）
family（Birc2, Birc3）, and members of the death domain
family（Cflar, Cradd, Fadd, Myd88, Tnfrsf1a, and Tn⁃
frsf11b）also belong to or relate to the p53 signaling
pathway ［59, 60］. The p53 signals have been associated
with GTP binding and GTPase mediated signal transduc⁃
tion［61］. The TRAF family may likewise play a role in
p53-mediated proapoptotic signaling in response to cel⁃
lular stress［62］. This suggests that p53 signaling can stim⁃
ulate a wide network of signals that act through numer⁃
ous apoptotic pathways. These include the extrinsic or
intrinsic death receptor pathways, including the TNF re⁃
ceptor family, which triggers the activation of a caspase
cascade that shifts the balance in the Bcl-2 family to⁃
wards many pro-apoptotic members and, consequently,
caspase-mediated apoptosis［63］.
Pifithrin- α（PFT）is a small, water soluble, lipo－
philic molecule and a powerful inhibitor of p53［64］. PFT
prevents the activation of p53 in cells treated with doxo⁃
rubicin, ultraviolet, etoposide, taxol, cytosine arabino⁃
side, and radiation and protects against heart and brain
ischemia and hyperthermia［65］. In cultured hippocampal
neurons, PFT protects neurons from amyloid B-peptide,
glutamate excitotoxicity, and camptothecin. This protec⁃
tive effect is associated with reduced expression of p53
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and Bax, as well as a reduction in mitochondrial damage
and caspase-3 activation［66］. PFT also protects against
heart and brain ischemia and hyperthermia［67］. In a pre⁃
vious study, PFT effectively protected cochlear and ves⁃
tibular hair cells by suppressing p53 phosphorylation in⁃
duced by cisplatin, while greatly reducing caspase-1
and caspase-3 activities［41］. In the current study, when
compared to cisplatin-treated cochlear tissue, adding
PFT significantly suppressed most early apoptotic
genes. The quantitative real-time PCR（qRTPCR） re⁃
sults also manifested a significant reduction in three ma⁃
jor genes（Bnip3, Gadd45a, and Mcl1）involved in the
p53 signaling pathway. The qRTPCR results confirmed
the super array data and provides an insight for the
mechanism PFT protection of cochlear hair cells against
cisplatin ［41］. These results have expanded our under⁃
standing of the role of p53 in cisplatin-induced apopto⁃
sis and the mechanism by which PFT affords its protec⁃
tive effects.
Platinum reagents enter mammalian cells mainly
through copper transporters［68－ 72］ and calcium channels
on the cell membrane［73, 74, 75］. Our previous study also re⁃
vealed that the tumor necrosis factor receptor-associat⁃
ed death domain（TRADD）was activated prior to cas⁃
pase-8 expression［27］. In view of the tumor necrosis fac⁃
tor receptors also being located on the surface of cell
membrane, we speculate that the platinum reagents may
cause a specific stimulation of the cell death receptors
on the cell membrane when they transit through the cell
membrane. The mechansns of cisplatin-induced stimu⁃
lation of cell death factor receptors remain unclear and
will be the target of our further research on cisplatin oto⁃
toxicity.
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